Fortuna Fix Appoints Dr. Stephen Shrewsbury To Their Leadership Team

Fortuna Fix (fka Ophiuchus Technologies) has hired Dr. Stephen Shrewsbury as Chief Medical Officer / EVP where he will serve as a key member of the Company leadership team as well as the leader of all regulatory and clinical affairs activity for the company. Prior to joining Fortuna Fix, Dr. Shrewsbury was SVP, Clinical Development & Chief Medical Officer at Aquinox Pharmaceuticals. Previously, Dr. Shrewsbury was SVP, Preclinical & Clinical Development and Chief Medical Officer of AVI BioPharma. From 2005 until 2009, he held similar roles at Adamas Pharmaceuticals and MAP Pharmaceuticals. Prior to that, Dr. Shrewsbury spent 10 years with Glaxo and Chiron launching notable respiratory programs such as Seretide in Europe and Flovent and Advair in the US. Dr. Shrewsbury received his medical degree from the University of Liverpool, UK and spent 13 years working in the UK National Health Service before entering the pharmaceutical industry